Analysis of the Predictive Efficacy of Serum suPAR Combined with APN and IgE Test and the Relationship of Patients with CHF and Cardiac Function.

Background: Chronic heart failure (CHF) is a complex cardiovascular disorder resulting from prolonged heart disease, leading to structural and functional damage, weakened myocardial contraction, and inadequate cardiac output for daily metabolism. The purpose of study is accurate evaluation and early identification of cardiac function and ventricular remodeling through effective biochemical indicators. Methods: This study, conducted from April 2020 to March 2021, included 100 CHF patients meeting the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2020 from First People's Hospital of Linping District, ascertaining a confirmed diagnosis based on these established guidelines. The objective of detecting these biomarkers is not for early diagnosis, given that the subjects are already diagnosed according to the guidelines. Instead, our focus is on using these biomarkers to assess disease severity, prognosis, or treatment response in the context of diagnosed CHF patients. Classification comprised 42 ischemic and 58 non-ischemic CHF cases, with NYHA cardiac function grading (I, II, III-IV) and left ventricular ejection fraction (LVEF) categorization (≤ 40%, >40%). A control group of 100 healthy volunteers was selected for comparison. SuPAR, APN, and IgE expressions were analyzed among different groups and LVEF categories. Diagnostic efficacy was assessed through ROC curves, and correlations with cardiac function and LVEF were explored. Results: SuPAR, APN, and IgE expressions were significantly higher in CHF patients compared to the control group. Increasing cardiac function grades in CHF patients correlated with a gradual elevation in suPAR, APN, and IgE expressions. Comparing LVEF groups, CHF patients with LVEF ≤ 40% exhibited significantly higher suPAR, APN, and IgE expressions. Combined detection of suPAR, APN, and IgE demonstrated superior diagnostic accuracy (AUC of 0.899) compared to individual markers. Positive correlations were observed between suPAR, APN, IgE, and cardiac function grades, while LVEF showed a significant negative correlation with these biomarkers. Conclusions: SuPAR, APN, and IgE expressions are elevated in CHF patients, and their combined detection serves as a highly efficient auxiliary diagnostic method. The findings offer valuable insights into the diagnosis and treatment of CHF patients.

Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention.

Background: Improving treatment outcomes in chronic heart failure (CHF) patients post percutaneous coronary intervention (PCI) is of significant importance. CHF is a prevalent and severe chronic condition that negatively impacts patients' quality of life and increases the risks of hospitalization and mortality. Therefore, evaluating effective treatment strategies is crucial in improving the prognosis of CHF patients after PCI. Objective: The main objective of this study was to evaluate the clinical efficacy of combining spironolactone with dbcAMP-Ca in CHF patients following PCI. The study aimed to assess the impact of this combination therapy on both clinical outcomes and left ventricular function. Methodology: The study design involved the random assignment of 110 CHF subjects post-PCI into two groups: a combination group receiving spironolactone with dbcAMP-Ca and a spironolactone-only group. The subjects' clinical efficacy, left ventricular function, plasma brain natriuretic peptide (BNP), serum uric acid (UA), serum high-sensitivity C-reactive protein (hs-CRP) levels, autonomic nerve function, and postoperative adverse reactions were assessed. Results: The results demonstrated that the combination group, receiving spironolactone with dbcAMP-Ca, showed superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function compared to the spironolactone-only group. Additionally, the combination group exhibited a lower incidence of adverse reactions and reduced levels of plasma BNP, UA, and hs-CRP. These findings indicate that spironolactone combined with dbcAMP-Ca has a favorable clinical effect in CHF patients post-PCI, effectively improving left ventricular and autonomic nerve function while maintaining high safety. Conclusions: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination therapy in the management of CHF patients in clinical settings.

Effects of the lncRNA MALAT1 gene region rs664589 site mutation on acute myocardial infarction in Chinese Han.

We aimed to study the association between the non-coding region of the lncRNA MALAT1 gene, the non-coding region rs664589 C>G variant, and the risk of acute myocardial infarction (AMI) in the Chinese Han population. 165 NSTEMI and 135 STEMI patients were enrolled in the study. An additional 150 healthy individuals were enrolled as the controls. All subjects were analyzed for the MALAT1 rs664589 locus genotype. The receiver operating curve (ROC) was used to determine the effect of MALAT1 rs664589 single nucleotide polymorphism (SNP) on the diagnosis of AMI by plasma lncRNA MALAT1. The MALAT1 rs664589 site G allele carrier was 1.39 times more likely to have NSTEMI than the C allele carrier (95% CI: 1.16-1.61, P = 0.001) and 1.59 times more likely to have STEMI than the C allele carrier (95% CI: 1.31-1.85, P < 0.001). The MALAT1 rs664589 site C>G mutation resulted in an increase in the area under the ROC curve (AUC) of the plasma lncRNA MALAT1 level for the diagnosis of AMI. The plasma lncRNA MALAT1 levels in AMI patients were negatively correlated with hsa-miR-1972, hsa-miR-194-5p, hsa-miR-4717-5p, hsa-miR-6735-3p, and hsa-miR-3677-5p (r = -0.81, -0.75, -0.66, -0.71, and -0.88). The C>G mutation of MAL6641 rs664589 causes an increased risk of AMI in the Chinese Han population. The SNP at this site affects the value of plasma lncRNA MALAT1 in the diagnosis of AMI. The specific mechanism may indicate that the C>G mutation of the MALAT1 rs664589 changes the regulation of miRNAs expression by lncRNA MALAT1.

Hydrogels Loaded with Atorvastatin-Metal Organic Framework Have a Preventive Effect on Coronary Heart Disease.

In the research, a new three-dimensional coordination polymer was synthesized by solvothermal method based on the metal ligand LCu =[Cu(2,4-pydca)2 ]2- (2,4-pydca=pyridine-2,4-dicarboxylate) and alkaline-earth ion CaII with chemical composition {[Ca(H2 O)2 ][LCu ]⋅DMSO ⋅ 2H2 O}n (1) (DMSO=dimethyl sulfoxide). The complex 1 was characterized soundly by Fourier transform infrared (FT-IR) spectroscopy, elemental analysis (EA), single-crystal X-ray diffraction (SCXRD) and thermogravimetric analysis (TGA). Using atorvastatin as drug model, carboxymethyl chitosan and calcium alginate as raw materials, a new type of metal gel particles was prepared. The microstructure of the gel was observed by scanning Electron Microscope (SEM) and its modulation effect on the activity of human cardiomyocytes was evaluated. The results show that the gel particles presented a three-dimensional porous structure and were able to significantly up-regulate the cell activity of human cardiomyocytes, which is expected to develop the metal gel particles into drugs for the treatment of coronary heart disease.

Correlations of visfatin with severity of acute myocardial infarction, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention.

Background: To investigate the relationship between visfatin level in the peripheral blood of patients with acute myocardial infarction (AMI) patients and the severity of AMI, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention (PCI). Methods: A total of 37 AMI patients diagnosed and treated in our hospital were selected as experimental group, and 35 patients with normal coronary angiography were enrolled as control group. The general pathological data and occurrence of atrial fibrillation after PCI of all the patients were recorded in detail, and the content of indexes related to the severity of AMI and visfatin was measured. Moreover, the correlations of visfatin with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI were explored.

Integrative bioinformatics analysis reveals STAT2 as a novel biomarker of inflammation-related cardiac dysfunction in atrial fibrillation.

Atrial fibrillation (AF) is a common critical cause of stroke and cardiac dysfunction worldwide with lifetime risks. Viral infection and inflammatory response with myocardial involvement may lead to an increase in AF-related mortality. To dissect the potential sequelae of viral infection in AF patients, especially the coronavirus disease 2019 (COVID-19), based on AF and COVID-19 databases from Gene Expression Omnibus, weighted gene co-expression network analysis was used to identify key genes in heart tissues and peripheral blood mononuclear cells. Here, HSCT, PSMB9, STAT2, and TNFSF13B were identified as common risk genes of AF and COVID-19 patients. Correlation analysis of these genes with AF and COVID-19 showed a positive disease relevance. silencing of STAT2 by small interfering RNA significantly rescued SARS-CoV-2 XBB1.5 pseudovirus-induced cardiac cell contraction dysfunction in vitro. In conclusion, we identified STAT2 may be a novel biomarker of inflammation-related cardiac dysfunction in AF.

Phase diagrams on composition-spread FeyTe1-xSex films.

FeyTe1-xSex, an archetypical iron-based high-temperature superconductor with a simple structure but rich physical properties, has attracted lots of attention because the two end compositions, Se content x = 0 and 1, exhibit antiferromagnetism and nematicity, respectively, making it an ideal candidate for studying their interactions with superconductivity. However, what is clearly lacking to date is a complete phase diagram of FeyTe1-xSex as functions of its chemical compositions since phase separation usually occurs from x âˆ¼ 0.6 to 0.9 in bulk crystals. Moreover, fine control of its composition is experimentally challenging because both Te and Se are volatile elements. Here we establish a complete phase diagram of FeyTe1-xSex, achieved by high-throughput film synthesis and characterization techniques. An advanced combinatorial synthesis process enables us to fabricate an epitaxial composition-spread FeyTe1-xSex film encompassing the entire Se content x from 0 to 1 on a single piece of CaF2 substrate. The micro-region composition analysis and X-ray diffraction show a successful continuous tuning of chemical compositions and lattice parameters, respectively. The micro-scale pattern technique allows the mapping of electrical transport properties as a function of relative Se content with an unprecedented resolution of 0.0074. Combining with the spin patterns in literature, we build a detailed phase diagram that can unify the electronic and magnetic properties of FeyTe1-xSex. Our composition-spread FeyTe1-xSex films, overcoming the challenges of phase separation and precise control of chemical compositions, provide an ideal platform for studying the relationship between superconductivity and magnetism.

Effects of Serum LDL-C, CysC, and D-D in Patients with Coronary Atherosclerotic Heart Disease.

Objective: To investigate the effects of low-density lipoprotein cholesterol (LDL-C) and serum cystatin C (CysC) combined with D-dimer (D-D) on patients with coronary atherosclerotic heart disease (CHD). Methods: 90 patients with CHD who were admitted to our hospital and diagnosed by coronary angiography (CAG) from February 2020 to June 2021 were selected as the study subjects. 90 patients were grouped according to different types and branches of coronary lesions, and 30 patients with outpatient health check-ups at the same period were selected as the control group, and the differences in serum LDL-C, CysC, and D-D levels between the groups were compared. The logistic regression model was built to explore risk factors affecting the occurrence of CHD. Also, receiver operating characteristic (ROC) curves were drawn to analyze the diagnostic value of LDL-C, CysC, and D-D in CHD. Results: In the comparison of LDL-C, CysC, and D-D levels, CHD group > control group (P < 0.05); stable angina (SAP) group > unstable angina (UAP) group > acute myocardial infarction (AMI) group (P < 0.05); three-branch group > two-branch group > single-branch group (P < 0.05). The logistic regression model showed that high expression levels of LDL-C, CysC, and D-D, male gender, and combined hypertension were risk factors for CHD. The area under the curve (AUC) of the combination of LDL-C, CysC, and D-D was 0.868, and the sensitivity and specificity were 88.89% and 73.33%, respectively, which are higher than those in single diagnosis (P < 0.05). Conclusions: LDL-C, CysC, and D-D are highly expressed in CHD samples, and the combination of the three is beneficial to enhance the diagnostic accuracy of clinical CHD.

Development and validation of a machine learning-based model for postoperative ischemic stroke in middle-aged and elderly patients with hip or knee arthroplasty.

Postoperative ischemic stroke in middle-aged and elderly patients with hip or knee arthroplasty remains a major postoperative challenge, little is known about its incidence and risk factors. This study sought to create a nomogram for precise prediction of ischemic stroke after hip or knee arthroplasty. Discharge data of all middle-aged and elderly patients undergoing primary hip or knee arthroplasty from May 2013 to October 2020 were queried. These patients were then followed up over time to determine their risk of ischemic stroke. Clinical parameters and blood biochemical features were analyzed by the use of univariable and multivariable generalized logistic regression analysis. A nomogram to predict the risk of ischemic stroke was constructed and validated with bootstrap resampling. Eight hundred twenty-eight patients were included for analysis; Fifty-one were diagnosed with ischemic stroke. After final regression analysis, age, the neutrophil-to-lymphocyte ratio (NLR), a standard deviation of red blood cell distribution width, American Society of Anesthesiologists, low-density lipoprotein, and diabetes were identified and were entered into the nomogram. The nomogram showed an area under the receiver operating characteristic curve of 0. 841 (95% confidence interval [CI], 0.809-0.871). The calibration curves for the probability of ischemic stroke showed optimal agreement between the probability as predicted by the nomogram and the actual probability (Hosmer-Lemeshow test: P = .818). We developed a practical nomogram that can predict the risk of ischemic stroke for middle-aged and elderly patients with hip or knee arthroplasty. This model has the potential to assist clinicians in making treatment recommendations.